NEW YORK, Sept. 12, 2013—Kantar Health, a leading global healthcare consulting firm, has appointed Dr. Pierre-Henri Delaage as Senior Director, Medical Affairs, based in Paris. In this role, he will provide market access, prelaunch, outcomes and late-phase research support to pharmaceutical company clients across France, Italy and Spain.
Dr. Delaage joins Kantar Health from AstraZeneca, where he was most recently senior manager of medical affairs and medical marketing responsible for assessing the value of Nexium and Crestor among payers, physicians and patients, helping the pharmaceutical manufacturer secure market access. He is a medical doctor who has practiced in hospitals in both France and the United States.
“With market access issues quickly becoming more complicated throughout the product lifecycle, it’s important to understand the roles all healthcare stakeholders have in navigating the regulatory process,” said Michel Murino, CEO, Southern Europe and France, Kantar Health. “Pierre-Henri brings to Kantar Health extensive experience both a practicing physician and in clinical development, as well as deep relationships with the key healthcare stakeholders. His expertise will strengthen Kantar Health’s capabilities in supporting product development across the lifecycle and will be instrumental in helping clients demonstrate value for their products while also guiding them through this critical process.”
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.